Safety & Side Effects
US$ 24.01
semaglutide and nafld Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease? Mechanism of Semaglutide in MASLD
Description
H., Lifshitz, L
There are no separate consultation fees, no membership add-ons, and no shipping charges
Hansoh Pharma is becoming an emerging leader in metabolic diseases, and we see Mercks expertise and capabilities as key to accelerating the development of this promising asset for patients worldwide.
Song Y, Li N, Jiang S, Wang K, Lv G, Fan Z, et al
Obesity is a complex condition but with the right support, its treatable
Still, like with any treatment, there are potential risks and side effects
